Real-world Effectiveness and Tolerability of Interferon-free Direct-acting Antiviral for 15,849 Patients with Chronic Hepatitis C: A Multinational Cohort Study
Fanpu Ji,Sally Tran,Eiichi Ogawa,Chung-Feng Huang,Takanori Suzuki,Yu Jun Wong,Hidenori Toyoda,Dae Won Jun,Liu Li,Haruki Uojima,Akito Nozaki,Makoto Chuma,Cheng-Hao Tseng,Yao-Chun Hsu,Masatoshi Ishigami,Takashi Honda,Masanori Atsukawa,Hiroaki Haga,Masaru Enomoto,Huy Trinh,Carmen Monica Preda,Phillip Vutien,Charles Landis,Dong Hyun Lee,Tsunamasa Watanabe,Hirokazu Takahashi,Hiroshi Abe,Akira Asai,Yuichiro Eguchi,Jie Li,Xiaozhong Wang,Jia Li,Junping Liu,Jing Liang,Carla Pui-Mei Lam,Rui Huang,Qing Ye,Hongying Pan,Jiajie Zhang,Dachuan Cai,Qi Wang,Daniel Q Huang,Grace Wong,Vincent Wai-Sun Wong,Junyi Li,Son Do,Norihiro Furusyo,Makoto Nakamuta,Hideyuki Nomura,Eiji Kajiwara,Eileen L Yoon,Sang Bong Ahn,Koichi Azuma,Kazufumi Dohmen,Jihyun An,Do Seon Song,Hyun Chin Cho,Akira Kawano,Toshimasa Koyanagi,Aritsune Ooho,Takeaki Satoh,Kazuhiro Takahashi,Ming-Lun Yeh,Pei-Chien Tsai,Satoshi Yasuda,Yunyu Zhao,Yishan Liu,Tomomi Okubo,Norio Itokawa,Mi Jung Jun,Toru Ishikawa,Koichi Takaguchi,Tomonori Senoh,Mingyuan Zhang,Changqing Zhao,Raluca Ioana Alecu,Wei Xuan Tay,Pooja Devan,Joanne Kimiko Liu,Ritsuzo Kozuka,Elena Vargas-Accarino,Ai-Thien Do,Mayumi Maeda,Wan-Long Chuang,Jee-Fu Huang,Chia-Yen Dai,Ramsey Cheung,Maria Buti,Junqi Niu,Wen Xie,Hong Ren,Seng Gee Lim,Chao Wu,Man-Fung Yuen,Jia Shang,Qiang Zhu,Yoshiyuki Ueno,Yasuhito Tanaka,Jun Hayashi,Ming-Lung Yu,Mindie H Nguyen
DOI: https://doi.org/10.14218/JCTH.2024.00089
2024-07-28
Abstract:Background and aims: As practice patterns and hepatitis C virus (HCV) genotypes (GT) vary geographically, a global real-world study from both East and West covering all GTs can help inform practice policy toward the 2030 HCV elimination goal. This study aimed to assess the effectiveness and tolerability of DAA treatment in routine clinical practice in a multinational cohort for patients infected with all HCV GTs, focusing on GT3 and GT6. Methods: We analyzed the sustained virological response (SVR12) of 15,849 chronic hepatitis C patients from 39 Real-World Evidence from the Asia Liver Consortium for HCV clinical sites in Asia Pacific, North America, and Europe between 07/01/2014-07/01/2021. Results: The mean age was 62±13 years, with 49.6% male. The demographic breakdown was 91.1% Asian (52.9% Japanese, 25.7% Chinese/Taiwanese, 5.4% Korean, 3.3% Malaysian, and 2.9% Vietnamese), 6.4% White, 1.3% Hispanic/Latino, and 1% Black/African-American. Additionally, 34.8% had cirrhosis, 8.6% had hepatocellular carcinoma (HCC), and 24.9% were treatment-experienced (20.7% with interferon, 4.3% with direct-acting antivirals). The largest group was GT1 (10,246 [64.6%]), followed by GT2 (3,686 [23.2%]), GT3 (1,151 [7.2%]), GT6 (457 [2.8%]), GT4 (47 [0.3%]), GT5 (1 [0.006%]), and untyped GTs (261 [1.6%]). The overall SVR12 was 96.9%, with rates over 95% for GT1/2/3/6 but 91.5% for GT4. SVR12 for GT3 was 95.1% overall, 98.2% for GT3a, and 94.0% for GT3b. SVR12 was 98.3% overall for GT6, lower for patients with cirrhosis and treatment-experienced (TE) (93.8%) but ≥97.5% for treatment-naive patients regardless of cirrhosis status. On multivariable analysis, advanced age, prior treatment failure, cirrhosis, active HCC, and GT3/4 were independent predictors of lower SVR12, while being Asian was a significant predictor of achieving SVR12. Conclusions: In this diverse multinational real-world cohort of patients with various GTs, the overall cure rate was 96.9%, despite large numbers of patients with cirrhosis, HCC, TE, and GT3/6. SVR12 for GT3/6 with cirrhosis and TE was lower but still excellent (>91%).